Developer docs
API playgroundTry for free, no card

Search company profiles

Janssen Belgium

Full company profile

uuid0009u44

Namestring
Janssen Belgium
Websiteurl
janssen.com
Company typeenum
Private
Founded yearint
1953
Descriptiontext

Janssen Belgium is a pharmaceutical subsidiary of Johnson & Johnson, headquartered in Beerse, Belgium, founded in 1953, and operating with a workforce of 10,000+ employees. Its therapeutic focus is oncology and hematology, anchored by two flagship assets: DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), which in November 2025 became the first and only FDA-approved treatment for high-risk smoldering multiple myeloma, and RYBREVANT (amivantamab), a subcutaneous EGFR/MET-directed bispecific antibody whose Phase 1b/2 data showed a 45% overall response rate in recurrent or metastatic head and neck squamous cell carcinoma. The company invests in proprietary drug-delivery technologies, including subcutaneous co-formulations, and supports these with internal R&D across exploratory biology, computational sciences, machine learning, and clinical innovation.

The business model operates through Johnson & Johnson's pharmaceutical segment, generating revenue by developing, manufacturing, and selling patented biologic therapies globally across the US and EMEA. Pricing is not publicly disclosed and reimbursement flows through national formularies, hospital systems, and private payers. In 2023 Janssen restructured by cutting its infectious disease and vaccine units, ending its prior Arrowhead Pharmaceuticals partnership and concentrating capital on oncology and hematology. Acquisition history includes XO1 (2015) and Corimmun (2012), both undisclosed-value deals that extended its pipeline. Customer reach is broad across patient populations, but revenue concentration sits in a narrow set of high-value oncology franchises, making pipeline success the primary value driver for the entity.

Short descriptiontext

Janssen Belgium is a Johnson & Johnson pharmaceutical subsidiary based in Beerse, Belgium, developing and commercializing oncology and hematology therapies including DARZALEX FASPRO and RYBREVANT for multiple myeloma and head and neck cancer patients globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
5,001–10,000
akta.pro rankint
HeadquartersBeerse, Belgium
HQ citystring
Beerse
HQ countrystring
Belgium
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
prescription pharmaceuticals, oncology therapeutics, hematology medicines, biopharmaceutical products, monoclonal antibody drugs
Industry4 codes
1Oncology & Hematology Pharmaceuticals
CodeHLAIAAACPrimaryYes
2Oncology Specialty Pharmaceuticals
CodeHLAIACAAPrimaryNo
3Immunology & Autoimmune Specialty Pharmaceuticals
CodeHLAIACABPrimaryNo
4Rare Oncology & Hematologic Malignancy Therapies
CodeHLAIAIACPrimaryNo
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
Product category
Oncology and Hematology Pharmaceuticals
Social media profiles1 record
Cost components6 values
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1DARZALEX FASPRO
Description

First and only FDA-approved treatment for high-risk smoldering multiple myeloma

prnewswire.com
+2 more records
Core offering1 text field

Janssen Belgium develops, manufactures, and commercializes pharmaceutical medicines focused on oncology and hematology therapeutic areas. Its product portfolio includes DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj), a subcutaneous treatment approved by the U.S. FDA for high-risk smoldering multiple myeloma, and RYBREVANT® (amivantamab), a subcutaneous bispecific antibody being evaluated for head and neck cancer and other EGFR/MET-driven solid tumors. The company operates as the pharmaceutical subsidiary of Johnson & Johnson.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Phase 3 study demonstrated significant reduction in disease progression for high-risk smoldering multiple myeloma patients
+1 more record
Product overview1 text field

Janssen Belgium operates as part of Johnson & Johnson's pharmaceutical division, focused on delivering innovative medicines. The product portfolio includes DARZALEX FASPRO® (the first and only FDA-approved treatment for high-risk smoldering multiple myeloma) and RYBREVANT® (amivantamab), a subcutaneous therapy demonstrating efficacy in head and neck cancer with broad potential across EGFR/MET-driven solid tumors. These treatments represent Janssen's oncology and hematology therapeutic areas.

Product and service2 records
1DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)
CategoryOncology / Hematology Pharmaceutical
Description

A subcutaneous monoclonal antibody treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma. It is the first and only approved treatment for this indication, based on Phase 3 study results demonstrating significant reduction in disease progression to active multiple myeloma.

2RYBREVANT® (amivantamab) Subcutaneous Formulation
CategoryOncology Pharmaceutical
Description

A subcutaneous bispecific antibody formulation of amivantamab being evaluated for treatment of recurrent or metastatic head and neck squamous cell carcinoma. Demonstrates broad potential across solid tumors driven by EGFR and MET pathways, with subcutaneous administration enabling improved patient convenience and dosing.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Arrowhead Pharmaceuticals
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Johnson & Johnson previously held a partnership with Arrowhead Pharmaceuticals through its Janssen subsidiary focused on infectious disease and vaccine development. J&J liquidated 247,598 Arrowhead shares, exiting its stake in the company. The partnership ended in 2023 after Janssen cut its infectious disease and vaccine units as part of strategic restructuring.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles24 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment3 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Janssen Belgium

Oncology and Hematology Pharmaceuticalsjanssen.com

Janssen Belgium is a Johnson & Johnson pharmaceutical subsidiary based in Beerse, Belgium, developing and commercializing oncology and hematology therapies including DARZALEX FASPRO and RYBREVANT for multiple myeloma and head and neck cancer patients globally.

What Janssen Belgium does

Janssen Belgium is a pharmaceutical subsidiary of Johnson & Johnson, headquartered in Beerse, Belgium, founded in 1953, and operating with a workforce of 10,000+ employees. Its therapeutic focus is oncology and hematology, anchored by two flagship assets: DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), which in November 2025 became the first and only FDA-approved treatment for high-risk smoldering multiple myeloma, and RYBREVANT (amivantamab), a subcutaneous EGFR/MET-directed bispecific antibody whose Phase 1b/2 data showed a 45% overall response rate in recurrent or metastatic head and neck squamous cell carcinoma. The company invests in proprietary drug-delivery technologies, including subcutaneous co-formulations, and supports these with internal R&D across exploratory biology, computational sciences, machine learning, and clinical innovation.

The business model operates through Johnson & Johnson's pharmaceutical segment, generating revenue by developing, manufacturing, and selling patented biologic therapies globally across the US and EMEA. Pricing is not publicly disclosed and reimbursement flows through national formularies, hospital systems, and private payers. In 2023 Janssen restructured by cutting its infectious disease and vaccine units, ending its prior Arrowhead Pharmaceuticals partnership and concentrating capital on oncology and hematology. Acquisition history includes XO1 (2015) and Corimmun (2012), both undisclosed-value deals that extended its pipeline. Customer reach is broad across patient populations, but revenue concentration sits in a narrow set of high-value oncology franchises, making pipeline success the primary value driver for the entity.

Janssen Belgium firmographics

Firmographics
Name
Janssen Belgium
Website
https://janssen.com
Company type
Private
Founded year
1953
Operating status
Operating
Headcount range
5,001–10,000 employees
Short description
Janssen Belgium is a Johnson & Johnson pharmaceutical subsidiary based in Beerse, Belgium, developing and commercializing oncology and hematology therapies including DARZALEX FASPRO and RYBREVANT for multiple myeloma and head and neck cancer patients globally.
Ownership category
akta.pro rank

Janssen Belgium industry classification

Industry
Product category
Oncology and Hematology Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
akta.pro primary industry
Oncology & Hematology Pharmaceuticals (HLAIAAAC)
akta.pro secondary industries
Oncology Specialty Pharmaceuticals (HLAIACAA), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Rare Oncology & Hematologic Malignancy Therapies (HLAIAIAC)

Keywords

  • Prescription pharmaceuticals
  • Oncology therapeutics
  • Hematology medicines
  • Biopharmaceutical products
  • Monoclonal antibody drugs

Where Janssen Belgium is headquartered

Location

Headquarters

HQ city
Beerse
HQ country
Belgium
HQ region
Europe

Markets served

Janssen Belgium business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure

Janssen Belgium product offering

Product offering

Core offering

Janssen Belgium develops, manufactures, and commercializes pharmaceutical medicines focused on oncology and hematology therapeutic areas. Its product portfolio includes DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj), a subcutaneous treatment approved by the U.S. FDA for high-risk smoldering multiple myeloma, and RYBREVANT® (amivantamab), a subcutaneous bispecific antibody being evaluated for head and neck cancer and other EGFR/MET-driven solid tumors. The company operates as the pharmaceutical subsidiary of Johnson & Johnson.

Product overview

Janssen Belgium operates as part of Johnson & Johnson's pharmaceutical division, focused on delivering innovative medicines. The product portfolio includes DARZALEX FASPRO® (the first and only FDA-approved treatment for high-risk smoldering multiple myeloma) and RYBREVANT® (amivantamab), a subcutaneous therapy demonstrating efficacy in head and neck cancer with broad potential across EGFR/MET-driven solid tumors. These treatments represent Janssen's oncology and hematology therapeutic areas.

Differentiator

Problem solved

Functional benefit

Brands

  • DARZALEX FASPRO: First and only FDA-approved treatment for high-risk smoldering multiple myeloma
  • RYBREVANT (amivantamab)
  • RYBREVANT

Products and services

  • DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) A subcutaneous monoclonal antibody treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma. It is the first and only approved treatment for this indication, based on Phase 3 study results demonstrating significant reduction in disease progression to active multiple myeloma.
  • RYBREVANT® (amivantamab) Subcutaneous Formulation A subcutaneous bispecific antibody formulation of amivantamab being evaluated for treatment of recurrent or metastatic head and neck squamous cell carcinoma. Demonstrates broad potential across solid tumors driven by EGFR and MET pathways, with subcutaneous administration enabling improved patient convenience and dosing.

Quantifiable outcome

  • Phase 3 study demonstrated significant reduction in disease progression for high-risk smoldering multiple myeloma patients
  • +1 more outcomes

Companies that use Janssen Belgium

Customer profile

Segments2 records

Ideal customer profiles1 record

Janssen Belgium technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Janssen Belgium partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Arrowhead PharmaceuticalsminorStrategic or Co-development Partner · 1 January 2023Johnson & Johnson previously held a partnership with Arrowhead Pharmaceuticals through its Janssen subsidiary focused on infectious disease and vaccine development. J&J liquidated 247,598 Arrowhead shares, exiting its stake in the company. The partnership ended in 2023 after Janssen cut its infectious disease and vaccine units as part of strategic restructuring.

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

Janssen Belgium competitors and assessment

Company assessment

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key highlights7 records

Customer concentration

Janssen Belgium social profiles

Digital presence

Janssen Belgium financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Janssen Belgium leadership team

Management profile

Number of profiles

Profiles24 records

Janssen Belgium funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Janssen Belgium M&A and investment

M&A and investment

M&A2 records

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Janssen Belgium

What does Janssen Belgium do?

Janssen Belgium develops, manufactures, and commercializes pharmaceutical medicines focused on oncology and hematology therapeutic areas. Its product portfolio includes DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj), a subcutaneous treatment approved by the U.S. FDA for high-risk smoldering multiple myeloma, and RYBREVANT® (amivantamab), a subcutaneous bispecific antibody being evaluated for head and neck cancer and other EGFR/MET-driven solid tumors. The company operates as the pharmaceutical subsidiary of Johnson & Johnson.

Is Janssen Belgium a public or private company?

Janssen Belgium is a private company. It is classified as corporate owned and is currently operating.

When was Janssen Belgium founded?

Janssen Belgium was founded in 1953. It employs 5,001 to 10,000 people.

Where is Janssen Belgium based?

Janssen Belgium is headquartered in Beerse, Belgium, in the Europe region.

Does Janssen Belgium have an API?

No public API is recorded for Janssen Belgium.

What industry is Janssen Belgium in?

Janssen Belgium's product category is Oncology and Hematology Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAIACAA, Oncology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceJohnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravisJohnson & Johnson presented new IMAAVY data at EAN 2026, including post-hoc analyses from the Vivacity-MG3 study showing greater MG-ADL score reductions and sustained meaningful clinical improvement in early-disease and lower-symptom patients. The company also outlined the PETUNIA study design to collect pregnancy outcomes data.BioSpaceNanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung CancerNanobiotix presented Part 1 data from the CONVERGE Phase 2 trial of JNJ-1900 (NBTXR3) in stage 3 inoperable lung cancer at ESTRO 2026. Early results showed an overall response rate of 85.7% (6/7 patients) and a complete response rate of 57.1% (4/7), with 100% disease control.BioSpaceProtagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda CollaborationProtagonist Therapeutics exercised its opt-out right under its Takeda collaboration for rusfertide, making it eligible for $400 million in opt-out payments ($200M now, $200M on FDA approval) plus a $75 million milestone. Total potential cash tied to the election and U.S. approval is $475 million, with up to $975 million in milestones and royalties.TulipWhat is Continuous Manufacturing? A Guide for Pharmaceutical…The pharmaceutical industry is increasingly adopting continuous manufacturing technologies to replace traditional batch production, aiming to streamline processes, reduce lead times from months to days, and improve quality control through real-time monitoring. Regulatory bodies like the FDA have supported this shift, with major firms such as Vertex Pharmaceuticals, Janssen, Eli Lilly, and Pfizer securing approvals for drugs produced via these integrated lines. Despite challenges regarding changeover complexity and economic investment, the trend is accelerating due to benefits in flexibility, reduced waste, and enhanced supply chain resilience.Urology TimesPremarket approval application initiated with FDA for companion diagnostic in bladder cancerPredicine, Inc. has initiated a premarket approval (PMA) application with the U.S. FDA for its PredicineCARE assay to be used as a companion diagnostic in bladder cancer. The company submitted the first module of the application, which includes documentation of its manufacturing and quality management systems, while further modules are planned following the completion of registrational trials. This development is supported by a collaboration with Janssen, a Johnson & Johnson company.L.E.K. ConsultingA View Into the Promise of Continuous ManufacturingThe article analyzes the growing adoption of continuous manufacturing (CM) in the pharmaceutical industry as a strategic alternative to traditional batch production, citing benefits such as reduced operational costs and improved supply chain resilience. Major pharmaceutical companies like Janssen and Pfizer are actively investing in CM infrastructure with specific targets for high-volume product production by 2025 and 2030 respectively. Despite challenges regarding capital investment and regulatory uncertainty, market analysts project significant annual growth driven by technological advancements and supportive frameworks from regulators like the FDA and WHO.GlobeNewswireJanssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Erdafitinib for the Treatment of Patients with Locally Advanced or Metastatic Urothelial CancerJanssen submitted a Marketing Authorisation Application to the EMA for erdafitinib in locally advanced or metastatic urothelial carcinoma with FGFR alterations. The submission is based on Phase 3 THOR study data showing median overall survival over one year. The company also submitted a supplemental NDA to the FDA for full approval.BenzingaCrude Oil Rises Over 1%; Cidara Therapeutics Shares Spike Higher - Aktis Oncology (NASDAQ:AKTS), AMC EnteThe article aggregates various market movements and corporate updates, highlighting that U.S. stocks traded lower while crude oil prices rose over 1%. Key corporate developments include Cidara Therapeutics shares spiking 20% after Janssen elected to proceed under a license agreement, and Palisade Bio shares surging 132% following an exclusive licensing deal with Giiant Pharma.BenzingaNanobiotix, NanoString Technologies And Other Big Stocks Moving Higher In Monday’s Pre-Market Session - BNanobiotix shares surged nearly 60% in pre-market trading following a license agreement with Janssen Pharmaceutical for the global co-development of NBTXR3, while NanoString Technologies and Black Diamond Therapeutics also saw significant gains driven by strong sales guidance and insider buying. Gorilla Technology Group continued its upward momentum after securing a $270 million contract with the Egyptian government, and Polestar reported a 36% year-over-year increase in second-quarter deliveries.GlobeNewswireJanssen Submits Marketing Authorisation Application to the European Medicines Agency (EMA) Seeking Approval of Single Tablet Combination Therapy (STCT) of Macitentan and Tadalafil for Treatment of PatJanssen submitted a marketing authorisation application to the EMA for a single tablet combination of macitentan and tadalafil for pulmonary arterial hypertension. The Phase 3 A DUE study showed a 45% reduction in pulmonary vascular resistance versus monotherapies. The company expects approval to cover all guideline-recommended treatment pathways.